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Summary The aim of this study was to determine the concentration of PDGF in vivo in neoplastic and
non-neoplastic brain lesions. Fluid from cystic lesions and cerebrospinal fluid was tested in a radioreceptor
assay that detects all described PDGF isoforms. High concentrations of PDGF were found in cyst fluids from
several astrocytomas, one metastatic melanoma, one metastatic lung adenocarcinoma and one intracerebral
abscess. The PDGF concentrations were several times higher than the levels known to be required for maximal
PDGF effects on cells in vitro. PDGF could also be detected in some non-neoplastic lesions, especially one
intracerebral abscess. The finding of high amounts of PDGF in neoplastic lesions strongly supports the
possibility that PDGF can be a mediator of tumour and stromal cell growth and motility in vivo. Comparison
of PDGF and P-thromboglobulin concentrations in the same fluids strongly indicates that the PDGF protein is
locally produced rather than a result of platelet activation and derangement of the blood-brain barrier.
Platelet-derived growth factor (PDGF) was originally recog-
nised as a serum growth factor for fibroblasts, vascular
smooth muscle cells and glial cells in culture (reviewed in
Heldin & Westermark, 1990; Raines et al., 1990). PDGF also
influences the growth of brain capillary vessels (Smits et al.,
1989), and is a chemotactic and angiogenic agent (Groten-
dorst et al., 1982; Siegbahn et al., 1990; Risau et al., 1992).
PDGF in serum originates from platelet a-granules, and
more recently it was realised that neuronal cells of the central
nervous system (CNS) constitute another important source of
PDGF in vivo (Sasahara et al., 1991; Yeh et al., 1991).
Structurally, PDGF is a 30 kDa dimer of two homologous
disulphide-bonded polypeptide chains denoted A and B,
which are encoded by different genes. All three possible
isoforms of PDGF have been identified and purified, namely
PDGF-AA, PDGF-BB and PDGF-AB (reviewed in Heldin
& Westermark, 1990; Raines et al., 1990). These bind to two
different but structurally related membrane receptors; all
three dimeric forms of PDGF bind to the a-receptor, whereas
the P-receptor has high affinity only for PDGF-BB and lower
affinity for PDGF-AB. Thus, binding of ['251I]PDGF-AA to
the a-receptor is competitively inhibited by all described
PDGF isoforms.
Several experimental findings suggsest that PDGF might
play a role in the pathogenesis of human tumours (for review
see Westermark et al., 1987). Several human tumour cell
lines, e.g. glioma (Nister et al., 1991), sarcoma (Pantazis et
al., 1985; Betsholtz et al., 1986), melanoma (Westermark et
al., 1986) and carcinoma (Rozengurt et al., 1985; Bronzert et
al., 1987; Peres et al., 1987) cell lines, produce PDGF in
culture. Malignant glioma cell lines express both PDGF A-
and B-chain genes or only PDGF-A (Nister et al., 1988a,
1991); however, they mainly secrete PDGF-AA into the ex-
tracellular medium (Hammacher et al., 1988; Nister et al.,
1988b), as do melanoma (Westermark et al., 1986) and sar-
coma (Betsholtz et al., 1986; Heldin et al., 1986) cell lines.
Human glioma cell lines also express PDGF receptors, so
that autocrine PDGF stimulation of these cells is possible
(Nister et al., 1991). The growth of at least some glioma cell
lines in vitro can actually be dependent on an autocrine
PDGF loop (Vassbotn et al., 1994).
It is thus possible that PDGF is one of the factors that
drives the proliferation and migration of spontaneously
occurring human primary and metastatic tumour cells within
the CNS, as well as the vascular proliferation necessary for
the growth of these lesions. The aim of this study was to
determine whether PDGF is present in neoplastic cystic brain
lesions of the CNS. The concentrations of PDGF in the
tumour cyst fluids and in fluid from non-neoplastic control
lesions were measured in a radioreceptor assay that detects
all described isoforms of PDGF.
Materials and methods
Specimens
Cyst fluids were obtained at surgery from 19 neoplastic (13
malignant astrocytomas, one low-grade astrocytoma, one
oligodendroglioma, one haemangioblastoma, one men-
ingioma, one metastatic malignant melanoma and one metas-
tatic pulmonary adenocarcinoma; Table I) and six non-
neoplastic cystic brain lesions (two arachnoid cysts, one glial
cyst in the right frontal lobe, one Dandy-Walker cyst, one
choroid plexus cyst in the fourth ventricle and one abscess;
Table II). Cerebrospinal fluid (CSF) was collected from some
of these patients, either by lumbar puncture or by ventricular
puncture (Tables I and II). CSF was also obtained from 26
additional patients, of whom 12 had neoplastic lesions (five
malignant astrocytomas and two low-grade astrocytomas,
one meningioma, one haemangioblastoma, one oligodendrog-
lioma, one metastatic mammary adencarcinoma and one
metastatic squamous cell lung carcinoma; Table III) and 14
had non-neoplastic lesions (three patients with subarachnoid
haemorrhage, two with cerebral infarction, two with head
injury, one with meningitis, one with arteriovenous malfor-
mation, and one with hydrocephalus due to aqueductal
stenosis). In addition, lumbar CSF was obtained from four
patients undergoing myelography for suspected lumbar disc
disease (Table IV). The CSF and cyst fluids were immediately
centrifuged at 900g and the supernatants frozen at -20°C
until required for analysis.
Assayfor PDGFa-receptor competing activity
The concentrations of PDGF were measured indirectly by
using an assay for PDGF a-receptor competing activity.
Human foreskin fibroblasts, AG 1523, were seeded in 12 well
plates, grown to confluence and washed once with binding
buffer (phosphate-buffered saline containing 1 mg of bovine
serum albumin, 0.01 mg ml-' calcium chloride dihydrate and
0.01 mg ml-' magnesium sulphate heptahydrate). The cells
were incubated at 4°C with the test fluids (diluted 1:5 in
binding buffer to a total volume of 0.5 ml) for 1.5 h. After
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washing with binding buffer, the cultures were further
incubated with ['25I]PDGF-AA (50,000 c.p.m. per well of
human recombinant PDGF-AA labelled to a specific activity
of 20,000-50,000 c.p.m. ng-' by the chloramine T method;
Hunter & Greenwood, 1962; Ostman et al., 1989) in 0.5 ml of
binding buffer for 1 h at 4°C, and washed six times with
binding buffer. Cell lysis was induced by adding 0.5 ml of
lysis buffer [1% Triton X-100, 20mM HEPES pH 7.4, 10%
(v/v) glycerol], at room temperature. After 20 min the Triton
X-100 lysate was sampled and the radioactivity was measured
in a gamma spectrometer. A standard curve was constructed
from results obtained with pure unlabelled human recom-
binant PDGF-AA (5-200 ngml-') and the PDGF a-receptor
competing activity of each sample was converted to the
equivalent concentration of PDGF (ngml-').
Some samples, diluted 1:5 in binding buffer, were prein-
cubated with 40gg ml- anti-PDGF immunoglobulin at 4C
overnight before adding them to the test cells as described
Table I Concentrations of platelet-derived growth factor (PDGF) and P-thromboglobulin
(P-TG) in cyst fluid and cerebrospinal fluid (CSF) from patients with neoplastic brain
lesions
Diagnosis
of lesion
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Malignant astrocytoma
Low-grade astrocytoma
Haemangioblastoma
Oligodendroglioma
Meningioma
Malignant melanoma
Lung adenocarcinoma
Cyst fluid
PDGF P-TG
(ngml-') (ngml-')
8 150
3 250
15 7
60 92
70 21
43 10
30 7
30 4
0 525
14 100
8 0
3 175
3 0
35 0
31 0
2 250
3 0
200 5
58 8
Table II Concentrations of platelet-derived growth factor (PDGF) and P-thromboglobulin
(P-TG) in cyst fluid and cerebrospinal fluid (CSF) from patients with non-neoplastic brain
lesions
Cyst fluid CSF
Patient Diagnosis PDGF P-TG PDGF P-TG
number of lesion (ngml') (ngml') (ngml') (ngml')
1 Glial cyst, right 25 0 0 75
frontal lobe
2 Choroid plexus 10 0
cyst, fourth ventricle
3 Dandy-Walker cyst 0 0 0 0
4 Arachnoid cyst 18 0
5 Arachnoid cyst 0 0
6 Abscess 113 0
Table III Concentrations of platelet-derived growth factor (PDGF)
and P-thromboglobulin (P-TG) in cerebrospinal fluid (CSF) from
patients with neoplastic brain lesions
CSF
Patient Diagnosis PDGF P-TG
number of lesion (ngml-') (ngml-)
1 Malignant astrocytoma 10 2
2 Malignant astrocytoma 0 0
3 Malignant astrocytoma 0 0
4 Malignant astrocytoma 0 0
5 Malignant astrocytoma 20 1
6 Low-grade brain stem 11 0
astrocytoma
7 Low-grade astrocytoma 0 0
8 Oligodendroglioma, 30 0
medulla oblongata
9 Haemangioblastoma 0 0
10 Meningioma 0 2
11 Breast adenocarcinoma 40 2
12 Lung squamous 0 0
cell carcinoma
Table IV Concentrations of platelet-derived growth factor (PDGF)
and P-thromboglobulin (P-TG) in cerebrospinal fluid (CSF) from
patients with non-neoplastic brain lesions
CSF
Patient Diagnosis PDGF P-TG
number of lesion (ngml') (ngml-')
1 Subarachnoid haemorrhage 0 5
2 Subarachnoid haemorrhage 15 2
3 Subarachnoid haemorrhage 0 0
4 Cerebral infarct lesion 10 0
5 Cerebral infarct lesion 0 0
6 Head injury 0 1
7 Head injury 0 0
8 Myelography patient 10 0
9 Myelography patient 0 0
10 Myelography patient 0 0
11 Myelography patient 0 0
12 Meningitis 10 3
13 Aqueductal stenosis 0 0
14 Arteriovenous malformation 15 0
Patient
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
CSF
PDGF
(ngmlh)
0
0
0
0
10
200
P-TG
(ngml-')
2
1
0
0
0
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above (Figure 1). The polyclonal antibodies used had been
raised in rabbits against purified human platelet PDGF (Hel-
din et al., 1981), and recognised all PDGF isoforms.
P-Thromboglobulin radioimmunoassay
P-Thromboglobulin (P-TG), which is present in platelets and
is released together with PDGF during the platelet release
reaction (Witte et al., 1978; Zahavi & Kakkar, 1980), was
also analysed in order to disclose the presence of serum-
derived proteins in the cyst and cerebrospinal fluids. A com-
mercial kit, the ,B-thromboglobulin (P-TG) RIA kit (Code
IM.88, Amersham International, Amersham, UK), was used
according to the vendor's description. The cyst and CSF
samples were tested at 1:25 dilution and the result obtained
for each sample was compared with that obtained with stan-
dard concentrations of P-TG provided in the RIA kit. The
normal concentration of ,B-TG should be 24-28 ng ml-' in
plasma and 10-25fLgml-' in serum, when the Amersham
RIA kit is used (vendor's description, cf. Bowen-Pope et al.,
1984). In order to ensure that the P-TG assay in our hands
could reliably detect even a low amount of contaminating
serum, we included serum and plasma from healthy individ-
uals (not shown).
Statistical analysis
Student's t-test was used to test for differences between
groups. The difference was considered statistically significant
when P<0.05. A simple regression analysis was performed
to evaluate the relationship between PDGF and P-TG con-
centrations.
Results
PDGFc-receptor competing activity in cyst and cerebrospinal
fluids
The concentrations of PDGF in cyst fluids and in CSFs are
presented in Tables I-IV. The samples were tested at 1:5
dilution, and the values shown represent the calculated con-
centrations in the undiluted samples. It is obvious that a
substantial amount of PDGF was present in cyst fluids from
most neoplastic lesions (mean 32 ng ml-', range
0-200 ngml-'; Table I). In 8 out of 14 astrocytomas the
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concentrations were estimated to be higher than 10ngml1,
with a maximum of 70 ng ml-', and only one sample gave a
completely negative result. High concentrations were found
in the two metastatic cases; 200 ng ml1l PDGF in the metas-
tasis of a malignant melanoma was the highest value
obtained in any of the fluids tested. Three out of five non-
neoplastic and non-infectious cysts (Table II) also contained
IOng ml' or more PDGF, with a maximum of 25 ngml'
(mean 11 ng ml1- , range 0-25 ng ml-'). There was no stati-
stically significant difference between neoplastic and non-
neoplastic lesions (P = 0.3). The low number of cases has to
be considered when interpreting this result. Comparison of
Tables I and II shows that the highest PDGF concentrations
in cyst fluids were found in the malignant lesions and in a
single infectious lesion. One intracerebral abscess was
estimated to contain 113 ng ml1 PDGF in the fluid sampled
from the cavity.
CSF samples from ten astrocytomas were also tested, and
three of them contained 10ng ml-' or more PDGF (mean
4ngml-', range 0-20ngml-'; Tables I and III). Thus, in
the astrocytoma patients, the PDGF concentrations in cyst
fluids were in general higher than in CSF (P= 0.02). This
also seemed to be true for the three patients in whom both
cyst fluid and CSF were available (Table I), but these cases
were too few to allow statistical analysis. However, CSF
from the patient with melanoma contained 200 ng ml-'
PDGF, as did the cyst fluid. Five out of 16 CSF samples
from non-neoplastic lesions contained 10 ng ml-' or more
PDGF (mean 4.0 ngml-', range 0- 15 ngml-'; Tables II and
IV). When the CSF samples from neoplastic and non-
neoplastic lesions were compared the mean values were
18 ng ml l' (range 0-200 ng ml l') and 4 ng ml1' (range
0-15 ng ml-') respectively (P = 0.2).
In order to ascertain that the activity measured in the
radioreceptor assay was specifically due to PDGF, a few test
samples were preincubated with anti-PDGF immunoglobulin
before applying them to the test cells. This procedure com-
pletely abolished the activity of these samples (Figure 1).
Human recombinant PDGF-AA at 30 ng ml- , with or with-
out preincubation with the immunoglobulin, was included as
a control in the same experiment.
Comparison with 13-thromboglobulin concentrations
The P-TG concentrations of cyst and CSF samples are given
in Tables I-IV. When evaluating the results one should
remember that the amount ofP-TG in platelets is 1,000 times
more than the amount of PDGF. Increased P-TG values, a
few times higher than the levels expected in plasma
(24-28 ng ml'), indicating some platelet activation, were
seen in some samples (Table I). In seven of the cyst fluid
samples collected from neoplastic lesions P-TG concentra-
tions were 50 ngml-' or higher, and in three of these cases
250ngml-' or higher (Table I). In these samples, except for
patients nos. 4 and 10, there were only low levels of PDGF.
The other neoplastic samples, as well as cyst fluid from
patients with non-neoplastic lesions, showed very low P-TG
values. Only one CSF sample, from a patient with a benign
glial cyst, contained more than 25 ngml-' P-TG, while the
P-TG levels in all other CSF samples were very low. There
was no increase in P-TG concentrations in fluids with the
highest PDGF concentrations. The regression analysis, in-
cluding the results of the two assays, showed no correlation
between the PDGF and P-TG concentrations (P = 0.2).
C AA 30 ng ml-' Pat. 1-5 c.f. Pat. 1-19 c.f.
Figure 1 Effect of anti-PDGF antibodies on PDGF ax-receptor
competing activity. Human recombinant PDGF-AA (AA
30 ngml-') and cyst fluid, diluted 1:5 in binding buffer, from
patients no. 5 (Pat. 1-5 c.f.) and no. 19 (Pat. 1-19 c.f.) in Table
I were tested in the ['25I]PDGF-AA radioreceptor assay as de-
scribed in Materials and methods. The samples were preincubated
at 4°C overnight with (U) and without (0) 40 lag ml-' anti-
PDGF immunoglobulin (Heldin et al., 1981). The control (C) is
binding buffer preincubated with and without the immuno-
globulin.
Discussion
This study shows that high amounts of PDGF are present in
the cyst fluid of most neoplastic lesions and also in CSF of
several of the patients. In order to determine if the measured
PDGF was a platelet release product or was locally pro-
duced, the concentration of ,B-TG was measured in the same
fluids. The concentrations of both PDGF and P-TG are
known to be very low in plasma (Zahavi & Kakkar, 1980;PDGF IN NEOPLASTIC AND NON-NEOPLASTIC CYSTIC LESIONS OF THE CNS 955
Bowen-Pope et al., 1984; Tahara et al., 1991). P-TG, like
PDGF, is normally contained in the platelet a-granules. It is
released together with PDGF in the platelet release reaction,
and is a sensitive indicator of platelet activation (Witte et al.,
1978; Zahavi & Kakkar, 1980; Bowen-Pope et al., 1984). A
positive correlation between PDGF and ,B-TG concentrations
would indicate that the PDGF in cyst and CSF samples is
derived from serum or plasma, and not from the tumour or
brain tissue itself. This possibility has to be considered since
the blood-brain barrier is deranged in tumours (Russel &
Rubinstein, 1989, and references therein), and plasma pro-
teins constitute a major fraction of gliomatous cyst fluid
proteins (Seitz & Wechsler, 1987; Lohle et al., 1992). High-
grade tumours in particular contain necrotic areas and
abnormal capillary vessels where platelets might aggregate
and release their products to be mixed with the plasma
proteins.
While the PDGF concentrations in the tumour cysts were
found to be many times higher than those expected in plasma
(Bowen-Pope et al., 1984; Leitzel et al., 1991; Tahara et al.,
1991), the P-TG levels were in general low. This finding
indicates that the measured PDGF was locally derived rather
than accumulating within the tumours as a result of platelet
activation and a locally deranged blood-brain barrier. The
PDGF concentrations were also higher in cyst fluid than in
CSF. Thus, the data indicate that PDGF could be produced
either by the tumour cells or by normal or reactive brain cells
surrounding the cysts. A derivation from tumour cells is
supported by previous investigations using in situ hybridisa-
tion and immunohistochemistry techniques that have shown
an increased level of PDGF mRNA and protein in human
malignant glioma cells relative to normal cerebral white mat-
ter (Maxwell et al., 1990; Hermanson et al., 1992).
High levels of PDGF were found not only in astrocytoma
cyst fluids, but also in the two metastatic lesions, with the
highest value in a patient with melanoma. Previous studies
have shown that a large proportion of melanoma cell lines
produce PDGF in vitro (Westermark et al., 1986). Our pres-
ent finding suggests that PDGF is also released by
melanomas in vivo, although we cannot exclude the pos-
sibility that PDGF present in cyst fluid is derived from cells
other than melanoma proper, such as endothelial cells. The
association of increased plasma PDGF levels with advanced
metastatic spread of breast carcinomas, without concomitant
platelet abnormalities, has been reported (Ariad et al., 1991).
Leitzel et al. (1991) also reported that cancer patients had
increased plasma PDGF levels.
An interesting finding was the large amount of PDGF in
the single sample from a cerebral abscess. It is well estab-
lished that PDGF is produced by macrophages (Martinet et
al., 1985); accumulation of such cells could explain the
finding. Since neuronal cells are sources of PDGF (Sasahara
et al., 1991; Yeh et al., 1991) it is not surprising to find
measurable amounts of PDGF in other types of non-neo-
plastic lesions.
The finding of PDGF in cyst fluid from neoplastic lesions
indicates that stromal cells as well as tumour cells are
exposed to the growth factor. Thus, tumour growth may
involve paracrine as well as autocrine activation of PDGF
receptors (Hermanson et al., 1992). The factor might
influence both cell growth and motility since it is both a
mitogenic and a chemotactic agent. Growth-promoting
activity (Persson et al., 1985; Westphal et al., 1989) and
growth factors other than PDGF (Prisell et al., 1987; Mor-
inglane et al., 1990) have been identified in cystic brain
tumours, and it is probable that PDGF acts in concert with
such factors. One goal of future therapy is the interruption of
autocrine and paracrine stimulatory loops within the tumour.
The identification of growth factors present in the tumour is
necessary to set the background for such therapeutic
strategies.
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